Early Biomarker Kidney Injury Assessment After Acumen Directed Fluid Management in Cardiac Surgery

Early Biomarker Kidney Injury Assessment After Acumen Directed Fluid Management in Cardiac Surgery

This study is to assess the benefits of goal-directed fluid management with ACUMEN in cardiac surgical patients and its impact on cardiac surgery-induced kidney injury.

This study is to assess the benefits of goal-directed fluid management with ACUMEN in cardiac surgical patients undergoing a CABG, AVR, or CABG/AVR. Kidney injury biomarkers NGAL, Uromodulin, and Hepcidin-25 will be used to assess cardiac-induced kidney injury. Patients will be randomly enrolled in either standard care for fluid management or goal-directed fluid management with ACUMEN.

Inclusion Criteria:

• Adult patients undergoing cardiopulmonary bypass
• Procedure coronary artery bypass grafting, aortic valve replacement, or both

Exclusion Criteria:

• Patients < 18 years old
• Emergent surgery
• Preoperative kidney disease (Cr > 2.0 or on renal replacement therapy)
• Ejection fraction < 40%
• Incomplete data in medical record